Pancreatic adenocarcinoma is a lethal disease. Over 80 % of patients are found to have metastatic disease at the time of diagnosis. Strategies to improve disease-specifi c outcome include identifi cation and early detection of precursor lesions or early cancers in high-risk groups. In this study, we investigate whether screening at-risk relatives of familial pancreatic cancer (FPC) patients is safe and has signifi cant yield.
INTRODUCTION
Pancreatic adenocarcinoma (pancreatic cancer) is a lethal disease with 42,470 new cases and 35,240 deaths projected in the United States for 2009 ( 1 ). Modern surgical management and better case selection have improved short-term survival (6 and 12 months) aft er resection ( 2 ) , but the overall 5-year survival rate for all stages remains around 5.0 % ( 3 ). Such poor outcomes result, in part, from the diffi culty of diagnosing this disease at an early stage. In those few patients diagnosed with small ( < 2 cm) cancers, the 5-year survival can approach 60 % ( 4 ). Identifying patients who have early, small, localized tumors at presentation, and developing a greater understanding of susceptibility and inherited risk could improve this poor overall survival rate.
Multiple risk factors for the development of pancreatic cancer have been identifi ed, including advancing age, male gender ( 5 ), tobacco use ( 6 ) , obesity ( 7 ), a family history of pancreatic cancer ( 8, 9 ) , certain other familial cancer syndromes ( 10 -12 ) , and chronic pancreatitis ( 13, 14 ) , both hereditary ( 15 ) and acquired.
Up to 10 % of pancreatic cancers in the United States are thought to have a familial origin ( 16 ) . Familial pancreatic cancer (FPC) is defi ned as pancreatic cancer, which occurs in families in which there are multiple fi rst and second degree relatives with pancreatic cancer and no known cancer syndrome. A prospective registry-based study estimated the risk of developing pancreatic cancer in healthy members of FPC families to be as high as 32-fold when three fi rst degree relatives in the family were aff ected with the disease ( 17 ) . Th is added risk of pancreatic cancer in unaff ected relatives of patients with pancreatic cancer in FPC families may make screening this subgroup worthwhile, perhaps improving survival by identifying pre-malignant precursor lesions or early stage pancreatic cancers.
Several pancreatic neoplasms have been proposed as precursor lesions in the spectrum of development of adenocarcinoma of the pancreas ( 18 -20 ) . Th ese include intraductal papillary mucinous neoplasms (IPMNs) ( 21 ) and microscopic pancreatic intraepithelial neoplasia (PanIN). IPMNs and PanINs probably develop into invasive pancreatic cancers via diff erent pathways ( 22 ) . In contrast to PanINs, IPMNs can be diagnosed by cross-sectional imaging studies and endoscopic ultrasound (EUS); these modalities can thus be employed for screening.
Previous studies have evaluated the feasibility and utility of screening for pancreatic cancer in high-risk relatives from FPC families using a combination of computed tomography scan (CT) EUS, and endoscopic retrograde cholangiopancreaticogram ( 23, 24 ) . Th e yield of signifi cant fi ndings was in the range of 5 -10 % . IPMNs have been identifi ed in these high-risk screened groups.
We prospectively studied asymptomatic at-risk relatives from a prospective screening of FPC families to determine the diagnostic yield of screening for pre-malignant pancreatic lesions and early stage pancreatic cancer.
METHODS

Patients
In December 2002, the Familial Pancreatic Tumor Registry (FPTR) at Memorial-Sloan Kettering Cancer Center (MSKCC) was established for patients with FPC and their at-risk relatives. Th is registry and the screening component reported in this study have both been reviewed by the Institutional Review Board of MSKCC. Criteria for entry into the FPTR as an at-risk relative include having one or more fi rst degree relative (FDR) with pancreatic cancer before age 50 years, two or more relatives with pancreatic cancer (one of whom is a FDR), three or more second degree relative (SDR) with pancreatic cancer, or a known BRCA mutation with one or more relatives with pancreatic cancer. Whenever possible, the diagnosis of pancreatic cancer in aff ected relatives is verifi ed through pathology reports.
Th e screening component of our program is off ered to relatives aged 35 years and over. All at-risk family members who are found to meet eligibility criteria are approached by a single experienced study assistant who reviews the risks and benefi ts of participation, and explains in detail the requirements for screening. If an individual agrees to participate in the registry, a detailed family history and epidemiology questionnaire are administered in person by the same study assistant. Genetic counseling is off ered to all eligible family members at study entry but completion of testing is not a requirement.
Th e screening process involves an offi ce visit, physical examination, and magnetic resonance cholangiopancreaticogram (MRCP) every year; CT is an acceptable substitute if subjects are unwilling to undergo MRCP. MRCP imaging at MSKCC is performed with a l.5-T superconducting magnet (General Electric Medical Systems, Milwaukee, WI) and a torso phased array coil. Breath-hold MRCP images are obtained using a single-shot fast spin-echo sequence. Th is eff ective TE was chosen to allow depiction of both pancreaticobiliary ducts and periductal tissues. Images are obtained as contiguous 4-mm thick slices in both axial and coronal planes, with a fi eld of view of 26 -40 cm. Field of view and numbers of slices are tailored to each patient using the minimum required to adequately image the pancreaticobiliary tree.
All studies included in this analysis were either conducted at MSKCC or images were reviewed by MSKCC physicians. MRCP was selected as initial screening modality because it is not invasive, has no associated radiation risks, and has an extremely low complication rate ( 25 ) .
Results of cross-sectional imaging are reviewed by a multidisciplinary team including hepatopancreatobiliary surgeons, gastroenterologists, interventional radiologists, medical and radiation oncologists, and radiologists specialized in crosssectional imaging. Aft er review, patients with lesions of concern (e.g., cystic lesions with a solid or nodular component, pancreatic duct dilation, pancreatitis or other lesions deemed concerning by the multidisciplinary group) are further evaluated by EUS with fi ne needle aspiration (FNA) for cytologic evaluation and cyst fl uid carcinoembryonic antigen as indicated.
EUS examinations are performed for patients found to have pancreas abnormalities on cross-sectional imaging by MRCP. All patients undergo standard video upper gastrointestinal endoscopy with attention to the ampulla of Vater using propofol sedation under the direction of an anesthesia team. EUS is performed by endoscopists experienced in endosonography using the GF-UM130, or GF-UE160 Olympus radial echoendoscopes and / or the GF-UC140P curvilinear array echoendoscope with switchable frequencies from 5 and 12-MHz (Olympus America, Lehigh Valley, PA), according to the preference of the physician.
Th e pancreas is imaged from the duodenum and stomach carefully scanning through the entire pancreas from the head to the tail, to identify parenchymal or ductal changes. Video and still images are obtained and interpreted at the time of the procedure looking for specifi c abnormalities of the pancreas such as solid or cystic mass lesions, focal cystic dilation, pancreatic duct wall thickening > 5 mm, or lymphadenopathy. If a signifi cant lesion is identifi ed, immediate FNA is performed using a 25-G needle, in the presence of a cytopathologist or cytotechnician to confi rm adequacy of the specimen.
Following the procedure, patients recover in a surgical day hospital and are discharged home the same day. A follow-up telephone call is made to the patient by a registered nurse the day aft er the procedure to document post-procedure clinical status and identify any procedure-related complications.
If the appearance of a lesion on EUS, cytology and / or carcinoembryonic antigen levels is suspicious for a pre-malignant or malignant pancreatic lesion, surgical consultation is obtained. Surgical intervention is based on multidisciplinary review with the fi nal decision resting with the surgeon and patient.
Statistical analysis
Descriptive statistics of the relatives who enrolled in the FPTR were compiled. Variables included gender, age, total number of relatives with pancreatic cancer, smoking history (never, past, and current, with those who smoked in the year before enrollment
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considered current smokers), body mass index at the usual adult weight, race, and religion.
Our question on the age of diagnosis of the relatives with pancreatic cancer allowed for responses in 10-year age categories, up to age ≥ 70. If a relative had pancreatic cancer and another cancer, we obtained the age at diagnosis of the fi rst cancer, which was not necessarily the pancreatic cancer. To calculate the average age at diagnosis of the youngest relative, we selected the appropriate relative and assigned the midpoint of the age range in the questionnaire, e.g., we used 44.5 for those diagnosed between 40 and 49 years, 54.5 for those diagnosed between 50 and 59 years, and 77 for those diagnosed at age ≥ 70 years.
Th us, the data on mean age of the youngest aff ected relative are an approximation. Information was missing or could not be classifi ed (because of multiple cancers in relatives) for 16 of the 309 relatives enrolled including 3 of the 109 who underwent surveillance. To compare the age of our study participants with that of their youngest aff ected relative, we classifi ed our subjects as to whether they were younger, in the same 10-year age range, or older than the youngest aff ected relative.
RESULTS
Between December 2002 and August 2009, a total of 542 eligible asymptomatic FPC family members were off ered entry into our FPC registry and 309 (57 % ) accepted. Of these 309, 161 (52.1 % ) agreed to be screened, and through 1 August 2009, 109 have completed at least one cycle of screening at MSKCC (range 1 -7). Demographics are shown in Table 1 .
In all, 98 / 109 (90.0 % ) of initial cross-sectional imaging studies performed were MRCPs. Th e screened population of 109 included 78 women (mean age 54 years) and 31 men (mean age 53 years). Among the 109 screened patients, 16 (14.7 % ) had one aff ected FDR. Among these 16 relatives, 9 were included because they had one aff ected relative diagnosed at < 50 years of age. Th e seven other patients were included because of a known BRCA mutation and a family history of pancreatic cancer. In all, 56 / 109 (51.4 % ) had two aff ected relatives, 21 (19.8 % ) had three, 11 (10.3 % ) had four, and 2.8 (3 % ) had fi ve aff ected relatives. Th e distribution of aff ected family members is seen in Figure 1 .
Of the 52 people without screening data, 36 had their scans performed at outside facilities and were therefore excluded from our analysis. Th e remaining 16 did not have scans done as of the cutoff date for the paper ' s analysis, 1 August 2009. Of those 16, seven have had scans since 1 August 2009. Nine relatives have had blood work only (three who refused scans, four lost to follow-up, two still pending scheduling a scan). Th e 52 relatives not included are not demographically diff erent from the 109 screened (same distribution of gender and age).
Screening results are summarized in Figure 2 . Of the 109 participants who completed at least one cycle of screening as of 1 August 2009, 18 (16.5 % ) had a prevalent abnormal fi nding on initial cross-sectional imaging ( Figure 3 ). Of these 18 relatives, 15 (83.3 % ) underwent EUS. Of the 15 patients who underwent EUS, nine had signifi cant fi ndings; eight of these patients underwent FNA. Th e remaining six relatives underwent EUS and had Aft er full evaluation of imaging and EUS / FNA results by our multidisciplinary team, surgical intervention was recommended for nine patients. Six have undergone surgical resection (two pancreatoduodenectomies and four distal pancreatectomies). Pathology revealed two main duct IPMNs, one PanIN 3, one PanIN 2, one T3N0 pancreatic cancer, and one serous cystadenoma with PanIN 1 in the specimen. Th ree patients had IPMN-like lesions on imaging (2 / 3 with only side branch changes) and EUS (FNA negative / non-diagnostic in all cases); these three patients refused surgery and remain under surveillance ( Figure 2 ; Table 2a ). Th e diagnostic yield of screening was 8.3 % (9 / 109) and 5.5 % (6 / 109) when only surgically confi rmed cases were included.
Ages of the individuals with signifi cant fi ndings are shown in Table 3 . Th e range was 46 -86 years and the median age was 68 years. Th e yield from screening was highly dependent on the age of the screened relative, with those ≥ 65 years having a sig- 
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Pancreatic Cancer Screening of At-Risk Relatives nifi cantly higher yield than those under 65 years. Th ere was no diff erence according to the age of the youngest relative with pancreatic cancer (data not shown). Representative images are seen in Figure 4a -c .
Six additional patients had normal MRCP initially and developed an abnormality (fi ve unilocular cysts and one multilocular cyst) on repeated surveillance scanning (mean 2.5 annual cycles, range 2 -4). Four of these six individuals underwent EUS and none were found to have signifi cant fi ndings aft er full multidisciplinary team review.
Th e remaining 85 at-risk relatives who participated in our screening program have had unremarkable cross-sectional imaging and continue to be followed with annual cross-sectional imaging.
We attempted to contact all relatives enrolled in the familial registry for interim follow-up by mailed questionnaire at 2 years from date of study entry; 241 of 309 total enrolled relatives reached eligibility for the 2-year follow-up questionnaire. Of these 241, 187 (77.6 % ) completed it and none reported newly developed neoplasm. In all, 131 of these 241 had agreed to surveillance: 84 / 94 (89.4 % ) who had scans done at MSKCC completed the interim history. In all, 26 / 28 (92.9 % ) relatives who had scans at outside facilities completed the questionnaire. None of the 55 / 89 (61.8 % ) relatives who completed the follow-up questionnaire developed pancreatic neoplasms during this interval.
No complications related to the contrast enhanced cross-sectional imaging studies were seen in any screening participants, and no patient required intravenous sedation for MRCP. In addition, all EUS ± FNA patients tolerated the procedure well and were discharged from the surgical day hospital recovery room in stable condition the same day as their procedure. Follow-up phone calls to each patient did not reveal any procedure related complications.
DISCUSSION
In our prospective, single-institution study, we screened relatives of pancreatic cancer patients who were at risk for pancreatic cancer due to their family history with MRCP. If pancreatic imaging was abnormal, EUS was performed with FNA of any suspicious lesion. Surgical consultation was obtained for patients with pancreatic lesions that were considered pre-malignant or malignant. As of August 2009, 109 relatives from FPC families have been screened with cross-sectional imaging at our institution. Nine individuals had initial imaging suggestive of a pancreatic precursor lesion or pancreatic cancer, and six have thus far undergone surgical resection. Our overall diagnostic yield from screening was 8.3 % .
Management of high-risk individuals from pancreatic cancer families is an important issue. A number of other FPTRs have been developed ( 26 ) and pancreatic cancer precursor lesions such 
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before the age of 50 years. For the latter criterion, we reasoned that genetics might have a stronger role in the etiology of pancreatic cancer in patients diagnosed at a younger age. In our study, MRCP was selected as the initial imaging modality because it is sensitive, non-invasive, does not involve radiation exposure, and has a very low complication rate ( 26 ) . Although EUS has been shown to be safe and eff ective in evaluating the pancreas for neoplastic lesions, it requires anesthesia, and has an associated complication rate generally felt to be approximately between 0.03 and 0.15 % ( 32,33 ). CT scan was not selected because of cumulative radiation exposure anticipated from serial scans.
All of our signifi cant lesions were found on initial screening (prevalent lesions). Th is is interesting and supports previous studies in which node positive cancers were found at " screening. " Th e utility of screening earlier than age 65 years is yet unanswered, as our study suggests that the highest yield was for relatives ≥ 65, this requires further study.
Th e six patients who developed abnormalities on subsequent scans -incident lesions -remain under surveillance but have not had any marked changes in their benign-appearing cystic lesions over 2 -4 years of follow-up. It is hard to draw a conclusion from this as the sample size is very small.
In spite of our broader defi nition of " familial, " we demonstrate a similar yield of signifi cant fi ndings ( Table 4 ). Although our defi nition of familial includes those recruited with only one fi rst degree relative diagnosed before the age of 50 years, this did not result in fewer signifi cant fi ndings. Additionally, we utilized only crosssectional imaging as the initial screening tool, recommending EUS only if an abnormality was found; this approach appears to be eff ective and safe.
What the optimal initial screen should be remains up for debate? Although we found our signifi cant yield using MRCP followed by EUS, the opposite strategy could have been employed with possibly equal eff ect. Our study was not designed to be comparative; i.e., our patients with MRCPs deemed " normal " did not undergo EUS to look for missed lesions. In addition, we had a sizable number of as IPMNs and PanINs have been well described ( 27 ) . Screening programs attempting to identify these pancreatic lesions in at-risk healthy family members are underway and several have reported their fi ndings. Brentnall et al. ( 28 ) at the University of Washington studied 14 individuals from three unrelated pancreatic cancer kindreds that had two or more aff ected members in at least two generations. Fourteen patients were evaluated. Seven (50 % ) of these patients had endoscopic retrograde cholangiopancreaticogram fi ndings of ectatic ducts. All seven patients were referred for pancreatectomy and found to have pancreatic duct epithelial dysplasia ranging from low to high grade. No invasive cancer was found. An additional study by the same group ( 29 ) confi rmed a high yield 12 / 43 (27.9 % ). Canto et al. ( 24 ) used EUS to screen 38 asymptomatic individuals from high-risk families. Six patients were found to have abnormalities and underwent resection. Two signifi cant lesions were found (one adenocarcinoma and one IPMN) for a screening yield of 5.3 % . Th e same group published a larger prospective, controlled study ( 25 ) using CT and EUS in78 high-risk FPC relatives, for an overall yield of 10.2 % .
Langer et al. ( 30 ) published their results of screening 76 individuals from 34 FPC families. No cancers were identifi ed and only one IPMN was found for a low diagnostic yield of 1.3 % . In comparison, Poley et al. ( 31 ) published the results of a prospective study utilizing EUS in 44 asymptomatic high-risk family members. Th ey found asymptomatic cancer in three patients (7 % ) and seven IPMN (16 % ). Th eir high yield likely was due to the inclusion of known carriers of familial atypical multiple mole melanoma syndrome, hereditary pancreatitis, Peutz-Jehgers, p53, and BRCA 1 and 2.
Our reports the largest number of healthy high-risk relatives screened at a single institution. Th ere is no consistent defi nition of FPC among centers undertaking these programs, and when we began our study we decided to be more inclusive in our defi nition, including those with only one fi rst degree relative with pancreatic cancer (as long as there were also other aff ected relatives), and also including individuals with only one fi rst degree relative diagnosed In 5 of 109 (4.6 % ) study subjects with abnormal imaging, IPMNs were suspected or confi rmed. Th is fi nding is similar to that of previous studies ( 24 -5,29,31 ) and strengthens the evidence for IPMN as a signifi cant pancreatic precursor lesion in FPC. Th e signifi cance of IPMN in FPC, however, remains unclear as these may simply represent the identifi able lesions as PanIN is typically diffi cult to identify either radiographically or endoscopically.
Our screening program enrolled 53 % of relatives who met criteria for screening. In all, 36 % of eligible relatives refused screening because they did not feel it would be useful. An additional 28 % found screening to be prohibitively expensive. Th e remainder of relatives either did not want an invasive procedure or gave no reason for declining screening. With increased validation of a yield in the 7 -10 % range, pancreatic cancer screening of at-risk relatives should become more widely accepted.
In conclusion, we believe screening will become an important tool in specifi c populations. Although to date, the question of whether screening improves mortality remains unanswered, our study supports and strengthens the fi ndings of previous investigators that screening at-risk relatives in FPC families has a diagnostic yield of 5 -10 % . Our yield of 8.3 % is consistent with these previous studies, despite our large group screened, defi nition of FPC, and diff erent mode of initial screening. Questions remain regarding the optimal groups to be screened for pancreatic precursor lesions and pancreatic cancer and the best protocol for such screening. Treating precursor lesions surgically appears to be a prudent strategy but larger longitudinal, multi-institutional follow-up studies will be required to demonstrate the ultimate goal of screening: a decrease in mortality from pancreatic cancer.
